Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
Abstract Purpose Malignant glioma (MG) is the most deadly primary brain cancer. Signaling though the PI3K/AKT/mTOR axis is activated in most MGs and therefore a potential therapeutic target. The mTOR inhibitor temsirolimus and the AKT inhibitor perifosine are each well‐tolerated as single agents but...
Main Authors: | Thomas J. Kaley, Katherine S. Panageas, Elena I. Pentsova, Ingo K. Mellinghoff, Craig Nolan, Igor Gavrilovic, Lisa M. DeAngelis, Lauren E. Abrey, Eric C. Holland, Antonio Omuro, Mario E. Lacouture, Emmy Ludwig, Andrew B. Lassman |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-04-01
|
Series: | Annals of Clinical and Translational Neurology |
Online Access: | https://doi.org/10.1002/acn3.51009 |
Similar Items
-
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.
by: Kenneth L Pitter, et al.
Published: (2011-01-01) -
Triggering of Eryptosis, the Suicidal Erythrocyte Death, by Perifosine
by: Jasmin Egler, et al.
Published: (2017-05-01) -
Correction: Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma
by: Kenneth L. Pitter, et al.
Published: (2011-01-01) -
Correction: Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma.
by: Kenneth L. Pitter, et al.
Published: (2011-01-01) -
Genome-wide identification of genetic determinants for the cytotoxicity of perifosine
by: Zhang Wei, et al.
Published: (2008-09-01)